Off-label promotion charges cost BI $95M in whistleblower deal
This article was originally published in Scrip
Executive Summary
With the help of an industry insider, the US Department of Justice snared another drug maker not playing by the rules in marketing its products – this time German pharma Boehringer Ingelheim, which agreed to pay $95 million to settle charges it improperly promoted its stroke-prevention drug Aggrenox (aspirin/extended-release dipyridamole), its chronic obstructive pulmonary disease (COPD) medicines Atrovent (ipratropium) and Combivent (albuterol/ipratropium), and the company's hypertension product Micardis (telmisartan).